Celgene and AstraZeneca/MedImmune are investigating the potential of PD-L1 inhibitors in hematologic malignancies.
Use the arrows on the slider below to navigate to a trial icon, then scroll down to view detailed information about the specific trial.
A phase 1b multicenter, open-label study to determine the recommended dose and regimen of durvalumab (anti–PD-L1 antibody) either as monotherapy or in combination with pomalidomide with or without low-dose dexamethasone in patients with relapsed and refractory multiple myeloma.
A phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide with and without dexamethasone in patients with newly diagnosed multiple myeloma.
A phase 2 multicenter, open-label study to determine the safety and efficacy for the combination of durvalumab and daratumumab in subjects with relapsed and refractory multiple myeloma (RRMM).
Multicenter, single-arm, phase 2 study to determine the efficacy for the combination of daratumumab plus durvalumab (anti–PD-L1 antibody) in patients with relapsed and refractory multiple myeloma (RRMM) who have progressed while on a current treatment regimen containing daratumumab
LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA
A phase 1/2 open-label, multicenter study to assess the safety and tolerability of durvalumab (anti–PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymphocytic leukemia.
DIFFUSE LARGE B-CELL LYMPHOMA
A phase 2 open-label, multicenter study to evaluate the safety and clinical activity of durvalumab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or with lenalidomide + R-CHOP in subjects with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL).
MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA
A randomized, multicenter, open-label phase 2 study evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab (MEDI4736) in previously untreated subjects with higher-risk myelodysplastic syndromes or in elderly patients (≥ 65 years) acute myeloid leukaemia subjects not eligible for hematopoietic stem cell transplantation.
A phase 2 international, multicenter, randomized, open-label, parallel-group study to evaluate the efficacy and safety of CC-486 alone and in combination with durvalumab (MEDI4736) in patients with MDS who fail to achieve an objective response to treatment with azacitidine for injection or decitabine.